CTLA4 and metastatic melanoma: In a subsequent study, same authors hypothesized that in patients with metastatic melanoma, CTLA-4 blockade might enhance the antitumor effect of IL-2, since IL-2 stimulates T-cell growth, but has also been implicated in the expansion of Tregs that express cell-surface CTLA-4.